To appreciate the involvement of known or potential susceptibility genes in sporadic breast tumors, we have searched for chromosomal deletions by studying loss of heterozygosity (LOH) at 43 microsatellite (CA) n markers from human chromosomes 10, 11 and 17, in 115 unselected consecutive samples of breast carcinoma with particular emphasis on speci®c regions. No site of consistent LOH was identi®ed on chromosome 10. Five regions of LOH were contained within bands q22-24 of chromosome 11 for which nearly 50% of the tumors had LOH at at least one marker. This region is thus a major site of deletion in breast cancer and several tumor suppressor genes seem to be involved. One of them may be the ataxia telangiectasia (ATM) gene which is located in one of the aected regions. Five regions of LOH, one of which is within the BRCA1 gene area, were recognized along chromosome 17. LOH at three of these regions were found in highly proliferative tumors. When combined with a previous study of chromosome 13 with emphasis on BRCA2 and Rb1 genes, this work allowed to distinguish a total of 12 regions of LOH, variably aected in breast tumors and correlated with prognostic parameters.
Introduction
Mutations in tumor suppressor genes seem important in the development of familial and so-called sporadic breast carcinomas. Several chromosome sites, suspected or known to contain such genes, are involved, often in the same tumor. Sites of potential alterations have been identi®ed by studying losses of chromosomal segments or by genetic linkage analysis in cancer prone families. Major regions of loss of heterozygosity (LOH) correspond to the location of known cancer genes, such as TP53 on the short arm of chromosome 17 and E-cadherin on chromosome arm 16q, or of putative tumor suppressor genes that have not been characterized yet. Segments of genome frequently deleted in breast tumors and suspected to contain tumor suppressor genes are on chromosome arms 1p, 1q, 3p, 6q, 7q, 8p, 11p, 11q, 13q, 16q, 17p, 17q, 18q and 22q (reviewed in Devilee and Cornelisse, 1994 and BieÂ che and Lidereau, 1995) . Linkage and mutation analyses have identi®ed the BRCA1 and BRCA2 genes, located on the long arm of chromosome 17 and 13 respectively, as major loci for hereditary breast cancer (Stzatton and Wooster, 1996, for review) .
In addition to BRCA1 and BRCA2, other loci, while being involved in breast cancer susceptibility, could also play a role in the development of sporadic breast tumors. Increased susceptibility to breast cancer has been noted in carriers of constitutional translocations involving the 11q23 band (Lindblom et al., 1994) . The possible involvement of the recently isolated (Savitsky et al., 1995) ataxia-telangiectasia (ATM) gene, located at 11q22-23, in breast cancer susceptibility has been suggested (Swift et al., 1987) . The importance of putative loci from chromosome region 11q22-23 in sporadic breast cancer, suspected after cytogenetic studies (Feri-Passantonopoulou et al., 1991; Hainsworth et al.,, 1991) , has been recently revealed by LOH analysis (Carter et al., 1994; Hampton et al., 1994a; Koreth et al., 1995; Windqvist et al., 1995) . Breast tumors are also frequently observed in patients with Cowden disease (Starink et al., 1986) . The gene for this syndrome has been mapped to chromosome region 10q22-23 (Nelen et al., 1996) .
We have looked for LOH at chromosome 10, 11 and 17, with special emphasis on regions hosting known or putative breast tumor susceptibility genes, i.e. 10q22-23, 11q22-24 and 17q-12-21. We have cumulated this analysis with a previous study of chromosome 13 where the BRCA2 gene is located, in order to evalaute the possible role in sporadic tumors of genomic regions which contain loci with either proven or potential involvement in mammary carcinogenesis and possible interactions between them. In addition, we have attempted a combined quantitative analysis of 12 de®ned regions of LOH with respect to histo-clinical parameters.
Results
For each chromosome, the largest number of microsatellites was chosen within or close to the regions of interest, i.e. 10q22-23, 11q22-24 and 17q12-21 to estimate the incidence of LOH. The other markers were used for comparison, to determine if this incidence was prominent for the given chromosome or if other regions exhibited LOH at a comparable or dierent frequency. The number of tumor samples tested varied from 67 to 115 depending on the marker.
LOH at markers from chromosome 10
Fourteen microsatellite markers were used to search for LOH at chromosome arms 10p and 10q. Six of them, from D10S201 to D10S185, are closely linked in a 15 cM interval (Gyapay et al., 1994; Dib et al., 1996; Moshonas et al., 1996) in the recently de®ned Cowden disease region, at 10q22-23. In linkage analyses (Nelen et al., 1996) , the maximum lod score was obtained with marker D10S573 and the most probable location of the diesease gene was de®ned between D10S215 and D10S564. Markers D10S532 and D10S541, which in our hands, gave better informativity, were used instead of D10S573 and D10S215, respectively (Gyapay et al., 1994) . Figure 1 presents a summary of the LOH results on this chromosome. Taking into account only informative cases, the percentage of LOH at each marker ranged from 13 ± 27% (Figure 1 ). Overall, this incidence was close to the general background we observed in previous studies (Kerangueven et al., 1995a,b,c) . LOH at markers from the Cowden region varied from 16 ± 23%, not above the average incidence noted all along the chromosome. Half of this was due to monosomies but some interstitial deletions were observed. However, they were distributed over the two arms and no precise region of consistent loss could be identi®ed.
The previous results provide evidence against the involvement of Cowden disease region in sporadic breast cancer. To further investigate the possible participation of chromosome region 10q22-23 in breast carcinogenesis, this time in genetic predisposition to breast cancer, and in other conditions than the Cowden disease itself, we set up a linkage analysis of breast cancer families. Seven families with breast cancer only syndrome, previously selected on the basis of absence of linkage to BRCA1 and BRCA2 linkage (Kerangueven et al., 1995b) were tested with markers D10S201, D10S532 and D10S541 as described (Kerangueven et al., 1995b) . Total cumulative lod scores were negative at several values of y (not shown). Lod scores were weakly positive (0.20) for D10S201 at y40.2 but this was dependent on one family only. Even if a lod score of 72 (hypothesis of independence) was not reached, the results are not in favor of the hypothesis of the Cowden disease gene being a BRCA gene. 
LOH at markers from chromosome 11
A total of 19 markers from chromosome 11 were studied. Figure 2 shows representative LOH and Figure 3 presents a summary of the results obtained in the 11q22-24 region. Taking into account only informative cases, the percentages of LOH at each marker ranged from 24 ± 26% at D11S901 and D11S917, to 41 ± 51% at D11S1356, D11S528 and D11S910 ( Figure 3 ). In contrast, LOH at markers from chromosome arm 11p did not exceed the 20% range (not shown) which, as previously mentioned above for chromosome 10 markers, correspond in our hands to a background of sporadic losses which does not allow the identi®cation of a particular region (Kerangueven et al., 1995a,b,c) . The incidence of 50% is in close agreement with ®ndings by other groups (Carter et al., 1994; Hampton et al., 1994b; Koreth et al., 1995) . The tumor samples could be separated into two distinct groups, according to their pattern of LOH. In a ®rst group of tumors, LOH was observed at all chromosome arm 11q markers, suggesting that inactivation of one allele of a putative tumor suppressor gene could have occurred in these tumors by large deletion or, in a few cases distinguished by LOH at chromosome arm 11p markers as well, by processes resulting in monosomy. A second group (as detailed in Figure 3 ) comprised tumors with LOH detected with only a restricted number of 11q markers, i.e. with interstitial deletions.
Five regions of consistent loss, designated a to e, all located in bands 11q22-24 (Van Heyningen and Little, 1995) , were identi®ed. They were centered on markers D11S1818 in the ATM gene area, D11S940 just centromeric, and D11S1356, D11S925 and D11S934, telomeric to ATM. Regions were de®ned on the basis of involvement of several tumors showing LOH and retention of heterozygosity at adjacent markers. For example, in Figure 3 , tumors 1288, 5809 and 5411 are used to de®ne region a, tumors 5411, 5510 and 5362 to de®ne region e. The distance between these regions is still important, and this certainly calls for a re®ned study. Importantly, region b contains the ATM locus, de®ned by markers D11S1343 to D11S2106 (Savitsky et al., 1995) .
LOH at markers from chromosome 17
Ten markers from chromosome 17 were studied to search for LOH at both arms, with emphasis on the BRCA1 gene region, at 17q21. Representative results are shown in Figure 4 and summarized in Figure 5 . Five regions of LOH, two on 17p, three on 17q, were individualized. One region of 17q, deleted in almost half of the tumor samples, was located within or near the BRCA1 gene area. Incidence of LOH in region e was low and identi®cation of this region could have been neglected, since as it was mentioned for chromosome 10 markers, it was close to the background value. It was only legitimized by the existence Figure 3 Schematic representation of the distribution of LOH at chromosome arm 11q in human breast tumors. At far left is a diagram of a portion of chromosome arm 11q, with the location of the microsatellite (CA) n markers as it is known to date (Gyapay et al., 1994; Van Heyningen and Little, 1995) . The middle panel is a schematization of allelic losses in representative tumors of the panel. Black lanes indicate LOH; absence of black lane means that the region is unaected. Numbers at far right represent the ratio of tumors with LOH vs the informative cases (the total number of analysed tumors was 115) for the selected markers (in the ATM region, numbers correspond to D11S1818 and D11S2106). Vertical bars on the right indicate common regions of minimal loss. Tumors with an ampli®cation of genes from the 11q13 band are designated with a black square on top 
Cumulative regional allelotyping
Even if some tumors presented interstitial deletions with markers of chromosome 10, the Cowden disease area, or any other portion of chromosome 10, was not considered as a major region of consistent loss. Our LOH analysis of three chromosomes with 43 markers thus allowed to de®ne 10 regions aected in breast tumors on chromosomes 11 and 17. A previous study of chromosome 13 with eight markers, allowed us to identify two additional regions of LOH, possibly associated with BRCA2 and Rb1 genes, respectively (Kerangueven et al., 1995a) .
We looked for correlations between clinico-pathological parameters and LOH at a given region, and performed a combined analysis on all 12 regions from chromosomes 10, 11, 13 and 17. This analysis, designated`cumulative regional allelotyping' (CRA), puts emphasis on quantitative data . The scoring of regions of LOH was done on 31 tumors tested with all markers (including chromosome 13 markers) as follows: scoring was done on two contiguous markers per de®ned region; a region was positive if LOH occurred at at least one marker, negative if the two alleles were present for each marker, or if one of the marker was non informative and the other has retained heterozygosity; the region was non informative in a given tumor if the two markers were non informative (accordingly, the proportion of tumors aected for each region varies slightly from the proportion aected for each marker).
CRA on a total of 12 regions of LOH distributed over the four chromosomes provided information (shown in Figures 6 and 7) on both the distribution of aected regions per tumor, and the proportion of aected tumors per region of LOH.
The proportion of aected tumors (31=100% of LOH) varied according to the region considered (Figures 6 and 7) . No region presented less than 30% or more than 60% of LOH (Figure 6a ). Two regions were deleted in the 30 ± 40% range, as shown in Figures 6a and 7 . The other 10 regions were aected in more than 40% of the cases. LOH at a given region of a chromosome arm was independent of LOH at other regions of the same arm and independent of LOH on a dierent arm or chromosome except in a few cases. LOH at regions 17b and 17c (P=0.013), at 13a and 13b (P=0.0001), and two regions from dierent chromosomes, such as 11a and 17d (P=0.005) were signi®cantly associated. When speci®c regions were considered, the proportions of LOH were as follows: the ATM gene region was involved in 48% of tumors, the BRCA1 gene region in 48% and the BRCA2 gene region in 52%. These ®gures for the three regions are strikingly close and may represent a maximum of incidence for a given gene.
The proportion of aected regions (12=100% of LOH) varied from tumor to tumor. Every tumor but three presented LOH at at least one region. Twelve tumors presented LOH at one, two or three regions only. Fourteen tumors showed LOH at more than 60% of the regions (Figure 6b ). This distribution showed clearly the existence of two groups of tumors, one with a low level of LOH (0 to 30%, in Figure 6b ) and one with a high level of LOH (from 40 to more than 90%). The tumors with a low level of LOH were characterized by a lower mitotic index (P=0.017). These two groups of tumors may be caused by dierent molecular alterations and may have distinct clinical evolutions. If Figure 7 Cumulative regional allelotyping of chromosomes 10, 11, 13 and 17. Relative frequencies (in %) of LOH at 15 regions (this presentation has correspondence in 6a). As indicated below, regions can be classi®ed in three classes according to frequency of involvement. No region is involved in less than 30 and more than 60% of tumors Sporadic breast cancer and susceptibility gene regions F Kerangueven et al this turns out to be the case, this type of cumulative analysis would be particularly helpful in assessing the initial prognosis.
Correlation with clinico-histological parameters
A statistical analysis of the correlations between LOH and clinico-pathological parameters was performed.
Among the 31 tumors, the ones with LOH at 13a (BRCA2 region) were associated with the presence of metastatic lymph nodes (P=0.007) and with an age below 50 (P=0.015). Tumors with LOH at regions 17a, 17b (P53 region) and 17c were highly proliferative. LOH at regions 17a ± c was indeed correlated with a high grade, due to a high mitotic index (P=0.02 to 0.005). However, LOH at region 17d (BRCA1) was not signi®cantly correlated with high grade, although we have observed a similar correlation between high mitotic index and BRCA1 gene germ line mutations . It is possible that dierent mechanisms of BRCA1 inactivation lead to tumors with distinct clinico-pathological parameters.
With respect to 11q markers, no strong correlation with any of the parameters was evidenced. Winqvist et al. (1995) found that LOH at 11q23 is predictive of aggressive postmetastatic course. Clinical follow-up of tumors from our panels will be done to assess this point. Ampli®cation of the 11q13-14 region has been detected in 15 ± 25% of breast carcinomas (Gaudray et al., 1992) . Such a process may alter the structure of chromosome arm 11q and lead to the loss of the remaining portion of the chromosome, creating LOH which could be falsely interpreted as the inactivation of a tumor suppressor gene. Upon examination of cases with both types of alteration (Figure 3 ), LOH at 11q23 did not seem to be associated with ampli®cation (as tested by Southern blot hybridization with several probes from 11q13 band -not shown) since loci telomeric of 11q13 (D11S919, D11S917) are retained in most cases. Furthermore, the possibility that the 11q13 band contains a tumor suppressor gene has been evoked (Zhuang et al., 1995) but was not apparent in our study. The same was true for chromosome arm 17q and ERBB2 ampli®cation.
Discussion
Our ®rst goal was to determine regions of LOH on speci®c chromosomes, i.e. chromosomes 10, 11 and 17, in breast tumors. In prostate cancer, LOH at 10q22-24, in a region slightly telomeric of the Cowden locus, has been evidenced (Gray et al., 1995; Ittman, 1996) and the role of PAC1, on 10pter-q11, and Mix1 at 10q25, two potential tumor suppressor genes, has been investigated (Gray et al., 1995; Sanchez et al., 1996) . However, in breast cancer, no evidence for the participation of genes from chromosome 10 could be obtained from the LOH data.
LOH at markers of chromosome region 11q22-23 has been observed in several types of cancer, including bladder (Shaw and Knowles, 1995) , cervical (Hampton et al., 1994b; Bethwaite et al., 1995) colorectal (Keldysh et al., 1993) , lung (Iizuka et al., 1995) , nasopharyngeal (Hui et al., 1996) , ovarian (Foulkes et al., 1993; Davis et al., 1996; Gabra et al., 1996) and stomach (Baa et al., 1996) carcinomas, and in melanomas (Tomlinson et al., 1993; Herbst et al., 1995) , and thus may host at least one so-called multiple tumor suppressor gene, the activity of which is not restricted to breast epithelial cells. Further studies will aim at re®ning the localization of this important locus. Unfortunately, because of the variability in the choice of the markers studied, it is dicult to determine if the 11q regions of most frequent LOH are the same in the dierent types of tumors. A survey of the various reports (also summarized in Davis et al., 1996 and in Hui et al., 1996) indicates that regions d and e reported here could be identical to two regions of LOH observed in ovarian cancers (Davis et al., 1996; Gabra et al., 1996) while regions b and d, which have already been evidenced in breast cancer by other authors are apparently also aected in bladder (Shaw and Knowles, 1995) , cervical (Hampton et al., 1994a) , lung , nasopharyngeal (Hui et al., 1996) and ovarian (Gabra et al., 1996) cancers. Alternatively, the 11q22-23 region may contain several tumor suppressor genes variably involved in dierent types of cancer. There are several potential candidates. Since the ATM gene has been suspected to play a role in cancer susceptibility (Swift et al., 1987) , its participation may be suspected. The involvement of the MLL/ALL1 gene (Rowley, 1993 ) located close to D11S1356 (Van Heyningen and Little, 1995) and which has been found to be deleted in a gastric carcinoma cell line (Baa et al., 1995) , or of unidenti®ed tumor suppressor genes, potentially also involved in familial cases (Lindblom et al., 1994; Sobol et al., 1994) , should also be investigated. One of the putative tumor suppressor genes may be a metastasis suppressor gene (Phillips et al., 1996) . The zebra pattern observed in this area is intriguing and needs further investigation with additional markers to obtain a better de®nition of the aected regions. In addition to being due to several potential tumor suppressor genes, special instability in the region may be responsible for the complexity of the LOH pattern.
Five regions of loss, two of them on 17p12-13, have been identi®ed by several authors in breast carcinomas and other cancers (Cropp et al., 1993; Kirchweger et al., 1994; Nagai et al., 1995; Schultz et al., 1996) and coarsely correspond to the ones de®ned here.
Our second goal was to determine whether the region containing known or putative breast tumor susceptibility genes were aected by LOH in sporadic tumors. This question has already been evoked and partly answered with respect to BRCA1 and BRCA2 gene regions (Cleton-Jansen et al., 1995; Cropp et al., 1993; Kerangueven et al., 1995a; Kirchweger et al., 1994; Nagai et al., 1995) . For the Cowden disease region, the low frequency of LOH and the absence of linkage to familial breast tumors both suggest that it is not prominently involved in cancer. However, it remains possible that the gene is involved in sporadic breast cancer by other ways than deletion. Our study of Cowden disease region in seven hereditary breast cancer families did not provide evidence for linkage, but it remains very preliminary and needs to be strengthened by an extensive study with more families and more markers. We also provided evidence for the possible involvement of the ataxia telangiectasia region in breast tumorigenesis. However, other regions with similar or greater frequency could be identi®ed nearby, and it is by no means certain that the gene involved in ataxia telangiectasia is the same as the one(s) involved in breast carcinogenesis. Finding so many sites of deletion in this region remains intriguing. It is possible that not all sites correspond to a bona ®de tumor suppressor gene and that some deletions are due to an overall greater instability of the region.
The third goal was to stress on the fact that a large number of genomic regions may host tumor suppressor genes involved in breast cancer and to suggest a way to analyse cumulative quantitative data. In contrast, our goal was not directed towards the re®nement of identi®ed regions, something that may be better performed on concentrating eorts on selected sites.
Materials and methods

Tumor samples
One hundred and ®fteen unselected primary breast carcinomas, and blood samples from the same patients, were collected at Institut Paoli-Calmettes in Marseille (48 tumors) and Institut Paul Lamarque in Montpellier (67 tumors). The following clinical and biological parameters were studied in this panel: tumor size, histoprognostic grade, lymph node (N) status (47% and 41% of N positive tumors, for the two panels, respectively), hormonal receptors (63% and 68% of estrogen receptor positive, 53% and 68% progesterone receptor positive), DNA index (70% with aneuploidy), S-phase, ERBB2, and p53 status. Genomic DNAs were extracted as previously described (Theillet et al., 1989) .
Genetic markers analysis
DNAs were examined for LOH with the following microsatellites (CA) n markers oriented according to recent consensus maps (Gyapay et al., 1994; Matise et al., 1994; Van Heyningen and Little, 1995; Dib et al., 1996; Moshonas et al., 1996) : Chromsome 10: D10S558,  D10S191, D10S199, D10S561, D10S201, D10S532,   D10S1644, D10S541, D10S564, D10S185, D10S534,  D10S186 and D10S212; chromosome 11: D11S922,  D11S904, D11S903, D11S901, D11S919, D11S917,  D11S940, D11S1343, D11S2179, D11S1818, D11S2106,  D11S1347, D11S1356, D11S528, D11S925, D11S1328,  D11S934, D11S910 and D11S969; chromosome 17:  D17S1174, D17S786, IG P53, D17S933, D17S855,  D17S1323 , D17S1327, D17S806, D17S785 and D17S928. Markers D10S532, D10S1644, D10S541 and D10S564 are located within or close to the Cowden locus region (Nelen et al., 1996) . Markers D11S1343, D11S2179, D11S1818, D11S2106 and D11S1347 are located within or close to the ATM gene region (Savitsky et al., 1995) . Primers were designed according to Gyapay et al. (1994) and Dib et al. (1996) , except for intragenic P53 IGP53 5'-AGGATAC-TATTCAGCCCGAGGTG-3', 5'-ACTGCCACTCCTTG-CCCCATTC-3'). Microsatellite analysis was performed using ampli®cation by polymerase chain reaction using a Perkin-Elmer Cetus thermal cycler, model 9600, and the resulting products were visualized and analysed with automated¯uorescent ABI 373 or 377 sequencing apparatus, as described (Kerangueven et al., 1995b,c) .
Statistical analysis
Signi®cances of dierences for contingency tables (2*2) were assessed by Chi-square (with Yate's correction) or Fisher's exact test when an expected cell value was less than n=5. Statistical analyses were performed using the EPI-INFO package, version 5.01. For contingency tables (R*C) with sparse data, the exact p value for KruskalWallis test (*,*) (Hollander and Wolfe, 1973; Agresti et al., 1990) was computed using the StatXact package (Cytel Software corp.).
